Clinical trial

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

NCT05241873

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2022-03-04

PhasePHASE1

Study timeline

Study start (actual)2022-03-04Date precision: day

Registry last updated2025-02-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Neoplasm Malignantunresolved

Carcinoma, Non-Small-Cell Lungunresolved

Respiratory Tract Neoplasmsunresolved

Neoplasmsunresolved

Neoplasms by Siteunresolved

Lung Diseasesunresolved

Respiratory Tract Diseaseunresolved

Carcinoma, Bronchogenicunresolved

Bronchial Neoplasmsunresolved

Adenocarcinomaunresolved

Carcinomaunresolved

Neoplasms by Histologic Typeunresolved

EGFR Exon 20 Mutationunresolved

EGFR Exon 20 Insertion Mutationunresolved

EGFR Activating Mutationunresolved

Antineoplastic Agentsunresolved

Metastatic Lung Cancerunresolved

Brain Metastasesunresolved

EGFR-mutated NSCLCunresolved

EGFR Atypical Mutations, Including G719X and L861Qunresolved

Interventions

CarboplatinDRUG · verified · RxNorm: carboplatin

PemetrexedDRUG · verified · RxNorm: pemetrexed

Sponsors & collaborators

Blueprint Medicines Corporationlead sponsor

Mapped research locations

New YorkNew York, United States2 BostonMassachusetts, United States2 SeoulSouth Korea2 TaipeiTaiwan2 HoustonTexas, United States1 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1 PhiladelphiaPennsylvania, United States1 TorontoOntario, Canada1 SeattleWashington, United States1 Washington D.C.District of Columbia, United States1 AuroraColorado, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05241873 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.